“So we're beginning to see an inflection point on Foundayo now, and with continued access growth and overall HCP adoption, we believe that we'll continue to see growth in Foundayo over the coming quarters.”

In context

“Ilya Yuffa (President, Lilly USA and Global Customer Capabilities): Sure. Thanks, Asad. For Foundayo, we're making meaningful progress on performance and building out the brand. As we said from the start, we're focusing on three key areas. One is educating physicians on the Foundayo profile and building out that experience. The second is achieving greater access and affordability for Foundayo and the third is building out consumer awareness. We're making progress on all three fronts. We're seeing the leading indicators being positive overall. We're seeing week-to-week growth in overall prescriptions and uptake for Foundayo. In the last 30 days, we've increased access with CVS, adding Foundayo in June. We've launched the Bridge program on July 1, and we started the launch of our full direct-to-consumer promotion campaign for Foundayo to build out consumer and physician awareness. In terms of overall growth and inflection, the last week of July we're seeing an inflection. We are almost doubling the volume that we had just a month ago. We're starting to see new starts such that nearly one out of four new starts are on Foundayo. So we're beginning to see an inflection point on Foundayo now, and with continued access growth and overall HCP adoption, we believe that we'll continue to see growth in Foundayo over the coming quarters.”